Diabetes devices in the hospital, two kidney medicines together, and a blood test for liver cancer
Five updates published between September 22 and 27 turn hospital care for diabetes devices, a two-drug kidney approach, semaglutide's heart benefit, cardiac rehabilitation timing, and liver cancer screening into practical questions for your next appointment.
Five documents published between September 22 and 27, 2026 touch each of the three conditions this brief follows. An international position statement takes on a question that catches people with diabetes off guard: what happens to a continuous glucose monitor, an insulin pump, or an automated insulin delivery system when its wearer is admitted to a hospital. A large real-world study measures what changes in chronic kidney disease when a GLP-1 medicine is added on top of an SGLT2 inhibitor. An analysis of a landmark heart trial asks how much of semaglutide's heart protection is explained by the weight the drug takes off. A registry of more than half a million heart failure hospitalizations looks at how much the timing of cardiac rehabilitation matters. And a blood test for liver cancer reports how it performed against the ultrasound that has been the standard screen for years.
The summaries below are background for your next appointment. Your clinician knows your history, your test results, and your current prescriptions, and treatment decisions belong in that conversation.
Quick view
| Update | What changed | Who may care | Action window | Appointment question |
|---|---|---|---|---|
| Diabetes devices in the hospital | An international position statement published September 22 sets out how to keep continuous glucose monitors, insulin pumps, and automated insulin delivery systems working safely during a hospital stay — covering which patients can manage their own devices, glucose targets, insulin dosing, care around surgery, alarm settings, staff training, imaging tests, and discharge. 1 | Adults with type 1 or type 2 diabetes who use a sensor, a pump, or an automated system — especially anyone facing a planned admission or an operation | Before a planned hospital stay, or at your next clinic visit | "If I am admitted, can I keep wearing and using my own devices, and who on the team will manage them?" |
| Kidney protection | Among 32,448 matched adults with chronic kidney disease, adding a GLP-1 medicine to an SGLT2 inhibitor already in use tracked with 30 percent fewer major kidney events, 17 percent fewer major cardiovascular events, and 45 percent lower death rates over a median 12 months. 2 | Adults with chronic kidney disease who already take an SGLT2 inhibitor, particularly those with obesity, heart failure, or coronary artery disease | Before your next kidney or diabetes visit — bring your current medication list | "I already take an SGLT2 inhibitor for my kidneys — would adding a GLP-1 medicine change my risk, and what side effects would I be trading for?" |
| Semaglutide and the heart | An analysis published September 23 found that the measured risk factors — waist size, inflammation, blood sugar, blood pressure, kidney measures — explain at most about a third of semaglutide's cardiovascular benefit in the SELECT trial, and possibly far less, leaving most of the effect unexplained. 3 | Adults taking semaglutide for weight and heart protection who have seen their weight level off | At your next visit — before you or anyone else reads a plateau as failure | "My weight has leveled off — does that change how much heart protection I am still getting?" |
| Cardiac rehabilitation | In 564,830 hospitalizations for acute heart failure, patients who received cardiac rehabilitation had lower in-hospital death rates than those who received none, and function at discharge was best when rehabilitation began within two to three days. 4 | Anyone hospitalized for heart failure, and the family members arranging care after discharge | Before you leave the hospital — ask for the referral in the room | "When should cardiac rehabilitation start for me, and how do I get enrolled before I go home?" |
| Liver cancer screening | In a prospective United States study published September 26, a multi-target blood test found 66.7 percent of early-stage liver cancers against ultrasound's 22.2 percent, but its specificity of 81.8 percent fell short of the study's own target and far behind ultrasound's 98.6 percent. 5 | Adults with cirrhosis or chronic hepatitis B who are due for routine liver cancer screening | At your next visit — and at every six-month screening appointment | "Am I due for liver cancer screening, which test are we using, and what happens if the result is abnormal?" |
1. In the hospital, your diabetes devices need a plan made in advance
Continuous glucose monitors, insulin pumps, and automated insulin delivery systems have become ordinary equipment for managing diabetes at home. Hospitals have been slower to catch up, and on September 22 an international group of clinicians published a position statement meant to close that gap. The statement appeared simultaneously in Diabetes Care and Diabetologia. 16
A position statement is not the same thing as a clinical practice guideline. It records what a group of specialists agree is reasonable practice, and this document leans on expert consensus wherever trials are thin. What makes it useful is how specific it is about the hospital itself.
The statement covers adults who are not critically ill — someone admitted for a few days with an infection or a heart problem, or someone arriving for a planned operation, rather than a patient in intensive care. The document addresses which patients are good candidates for managing their own devices from a hospital bed, what glucose numbers to aim for, how insulin should be adjusted, how to handle the hours around surgery, how alarms should be set so a low blood sugar is caught overnight, which staff need training, how device data should reach the medical record, and what discharge planning should look like.
Two of those topics deserve naming. The first is imaging: some scans require a device to come off, and the statement asks care teams to plan that in advance so the patient is not left without glucose readings for hours. The second is the way out of the hospital. The statement asks the team to restore the patient's own devices, restart the usual routine, and hand over a clear plan before discharge — the point at which home equipment and hospital equipment most often get out of step.
Ask at your next visit: "If I am admitted to the hospital, can I keep using my own sensor, pump, or automated system, and who on the team will be trained to manage them?"
2. In kidney disease, the question is what to add to the first medicine
Chronic kidney disease is where diabetes and heart disease overlap most, and two drug families already have a firm place in its treatment: SGLT2 inhibitors, which lower pressure inside the kidney's filtering units, and GLP-1 receptor agonists, which were developed for diabetes and weight and turned out to protect the heart and kidneys too. What has been less clear is what happens when a patient takes both. A study published September 27 in Diabetes, Obesity & Metabolism put a number on that question. 2
The researchers drew on a global records network covering 112,596 adults with chronic kidney disease. Of those, 16,460 began a GLP-1 medicine after already taking an SGLT2 inhibitor, and 96,136 stayed on the SGLT2 inhibitor alone. To make the two groups comparable, the researchers matched 16,224 pairs of patients on age, other conditions, medications, and laboratory values, then followed them for a median of 12 months.
Adding the GLP-1 medicine tracked with 30 percent fewer major adverse kidney events — a combined endpoint covering kidney failure and major loss of kidney function — with a hazard ratio of 0.70. The same group had 17 percent fewer major cardiovascular events (0.83) and 45 percent lower all-cause mortality (0.55). The pattern held across stages of kidney disease and whether or not the patient had diabetes, and it was strongest in patients with obesity, heart failure, or coronary artery disease.
The trade-offs moved in both directions. Gastrointestinal symptoms, genital infections, and progression of diabetic retinopathy were more common in the combination group. Problems from fluid loss and acute kidney injury were less common.
This is an observational study built from health records, and that shapes what it can support. Patients who received the second medicine may differ from those who did not in ways no record captures, and the paper itself calls for randomized trials to confirm the finding. The practical value here is as a question to raise, not a change to make on your own.
Ask at your next visit: "I already take an SGLT2 inhibitor for my kidneys — would adding a GLP-1 medicine change my risk, and what side effects would I be trading for?"
3. Semaglutide protects the heart by more than weight loss alone
In the SELECT trial, adults with existing cardiovascular disease and a body mass index of 27 or higher, none of them with diabetes, took weekly semaglutide at 2.4 milligrams and had 20 percent fewer major cardiovascular events than those taking a placebo. That result raised an obvious question. Was the drug protecting arteries directly, or was it protecting them only because the drug produced weight loss?
An analysis published September 23 in the European Heart Journal tried to divide the credit. 3 The researchers measured how much each of several changes over the first 24 months — waist circumference, body weight, inflammation as high-sensitivity C-reactive protein, HbA1c, lipids, blood pressure, kidney function, and urine albumin — could account for the reduction in heart attacks, strokes, and cardiovascular deaths.
Waist circumference produced the largest single estimate, at 64 percent of the benefit. Inflammation came next at 42 percent, then HbA1c at 29 percent and body weight at 19.5 percent. Every one of those figures arrived with a confidence interval so wide that it crossed into values that cannot be true: the waist circumference range ran from 27.5 percent to 179.6 percent. The authors' own supplementary checks suggested that the weight and waist estimates were unreliable.
Taken together, all the measured factors accounted for an estimated 31.4 percent of the benefit, with a range running from minus 30 percent to 144 percent. The most honest reading of the paper is that no more than roughly a third of semaglutide's cardiovascular protection, and possibly much less, can be attributed to the risk factors researchers know how to measure.
The trial's benefit was real. The explanation is incomplete — weight loss and falling inflammation are part of the story, and something else is at work that nobody has identified yet. That matters for anyone who has watched the scale stop moving. A weight plateau is not evidence that the medicine has stopped protecting the heart, and it is not a reason to stop a medicine on your own.
Ask at your next visit: "My weight has leveled off — does that change how much heart protection I am still getting from this medicine?"
4. Cardiac rehabilitation helps most when it starts early
Cardiac rehabilitation is supervised exercise and education that helps a patient rebuild strength and confidence after a heart event. Cardiologists agree it works in heart failure. What has been less settled is how soon after admission it should begin. A study published September 24 in the Journal of the American Heart Association used a national Japanese registry covering 564,830 hospitalizations for acute heart failure between 2012 and 2023 to look for an answer. 4
Roughly half of those patients received no cardiac rehabilitation at all — 275,454 of them. The rest were sorted by how quickly rehabilitation began after admission: one day or less, two to three days, four to five days, or six days and later. The researchers balanced the groups on 32 characteristics, including age, other illnesses, and how sick each patient was.
Every rehabilitation group had lower in-hospital death rates than the group that went without it, with adjusted odds ratios between 0.39 and 0.49. Function told a more specific story. Measured by the Barthel Index, a standard score for daily activities, patients who started rehabilitation within two to three days did best, and starting later than six days gave less benefit. The lowest death rates appeared across a broader window, around six days, which suggests that survival and physical function respond to different timelines.
This is a registry study, not a trial. It covers one country's hospitals, it looked only at what happened during the hospital stay, and the authors say the pattern needs prospective testing. What it supports is a question to ask in the hospital room, not a fixed rule.
Ask at your next visit: "If I am hospitalized for my heart failure, when should cardiac rehabilitation start for me, and how do I get enrolled before I go home?"
5. A blood test narrows the gap in liver cancer screening
Liver cancer screening in the United States leans on an abdominal ultrasound every six months for people with cirrhosis or chronic hepatitis B. Ultrasound is inexpensive and safe, but it misses early tumors often, and it performs worst in exactly the patients who need it most — people with obesity or fatty liver disease, whose extra tissue makes the images harder to read.
A blood test that performed better would be worth having. On September 26, the Journal of Hepatology published results from ALTUS, a prospective study run at multiple centers in the United States that put one such test head to head against ultrasound. 5 The study enrolled 3,089 adults with cirrhosis or chronic hepatitis B who were already eligible for routine screening. Of those, 2,293 had usable results from both the blood test and the ultrasound, and every participant also had a CT or MRI scan, which served as the reference standard. Thirty-seven liver cancers were found, 27 of them early enough to be classified as early stage.
For early-stage cancer, the blood test detected 66.7 percent of cases and ultrasound detected 22.2 percent. Across all stages the gap was similar: 73.0 percent for the blood test against 29.7 percent for ultrasound. The blood test therefore met the study's non-inferiority goal and then beat it, with a paired difference of 44.4 percentage points. No serious harm came from the blood draws.
The other half of the result matters just as much. Specificity — the ability to correctly report that no cancer is present — was 81.8 percent for the blood test and 98.6 percent for ultrasound. The blood test missed the study's own prespecified target of 82 percent, and it generates far more false alarms than ultrasound does. Each false alarm leads to more imaging and more waiting, which carries its own cost for the patient.
This is a strong result for a screening test, and it is not yet a screening recommendation. The study was a cross-sectional analysis inside a prospective study, and the field will want evidence that finding cancers earlier this way actually changes outcomes. In the meantime, screening ultrasound remains the standard of care. If you have cirrhosis or chronic hepatitis B, the practical step is to keep the appointments — six months comes around quickly — and to ask which test is being used.
Ask at your next visit: "Am I due for liver cancer screening, which test are we using, and what happens if the result comes back abnormal?"
Questions to take to your appointment
- "If I am admitted to the hospital, can I keep using my own sensor, pump, or automated system, and who on the team will be trained to manage them?"
- "I already take an SGLT2 inhibitor for my kidneys — would adding a GLP-1 medicine change my risk, and what side effects would I be trading for?"
- "My weight has leveled off — does that change how much heart protection I am still getting from this medicine?"
- "If I am hospitalized for my heart failure, when should cardiac rehabilitation start for me, and how do I get enrolled before I go home?"
- "Am I due for liver cancer screening, which test are we using, and what happens if the result comes back abnormal?"
References
- 1
- 2
- 3
- 4
- 5
- 6
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.